Skip to main content

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM

Trial Status: Active

A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

Inclusion Criteria

  • Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
  • At least 4 weeks (112 days) from last induction cycle of combination/multi-agent cyto-reductive chemotherapy and no single agent chemotherapy/maintenance within 7 days (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc).
  • Eligible for Autologous Hematopoietic stem cell transplantation according at the investigator discretion.
  • The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Adequate organ function at baseline .
  • Subjects must use effective contraception.

Exclusion Criteria

  • Previous history of autologous or allogeneic-HCT
  • Failed previous HSC collections or collection attempts.
  • Patients whose apheresis product were to be further selected and purified
  • Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
  • Dexamethasone: 7 days
  • Thalidomide: 7 days
  • Lenalidomide: 7 days
  • Pamolidomide: 7 days
  • Bortezomib: 7 days
  • Carfilzomib: 7 days
  • G-CSF: 14 days
  • GM-CSF or Neulasta®: 21 days
  • Combination/multi-agent cyto-reductive therapy
  • Erythropoietin or erythrocyte stimulating agents: 30 days
  • Eltrombopag, romiplostim or platelet stimulating agents: 30 days
  • Carmustine (BCNU): 42 days/6 weeks
  • Received >6 cycles lifetime exposure to Lenalidomide.
  • Received >2 cycles of alkylating agent combinations.
  • Received 3-bis(2-chloroethyl)-1nitrosourea (BCNU or Carmustine) within 6 weeks prior to anticipated first dose of G-CSF.
  • Received prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).
  • Received marrow stimulating factors:
  • Received G-CSF within 14 days prior to anticipated first dose of G-CSF.
  • Received Pegfilgrastim (GM-CSF or Nulesta) within 3 weeks prior to anticipated first dose of G-CSF.
  • Received erythrocyte of platelet stimulating agents within 30 days prior to anticipated first dose of G-CSF
  • Plans to receive maintenance treatment within 100 days post-engraftment (e.g. Lenalidomide, Bortezomib, Pomalidomide, Thalidomide, Carfilzomib, etc.)
  • Has received a live vaccine within 30 days of the planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
  • Known active CNS metastases or carcinomatous meningitis.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
  • Has an active infection requiring systemic therapy or uncontrolled infection. Has a known additional malignancy that is progressing or requires active treatment. Has an underlying medical condition that would preclude study participation.
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  • O2 saturation < 92% (on room air). 19. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death.
  • History or family history of Long QT Syndrome or Torsade de Pointes. Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or NYHA Heart Failure Class >2. QTcF > 470 msec, PR > 280 msec, Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial treatment.
  • Has a known history of HIV (HIV 1/2 antibodies), active / chronic Hepatitis B or C.


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE
Contact: Vlad Kustanovich
Phone: 310-206-5755


University of Miami Miller School of Medicine-Sylvester Cancer Center
Status: ACTIVE


Kansas City
University of Kansas Cancer Center
University of Kansas Hospital-Westwood Cancer Center
Status: ACTIVE


University of Maryland / Greenebaum Cancer Center
Status: ACTIVE
Contact: Sunita Philip
Phone: 410-328-8199


Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE


OHSU Knight Cancer Institute


M D Anderson Cancer Center
Status: ACTIVE


Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE


Fred Hutch / University of Washington Cancer Consortium

- Part 1: This lead-in period designed to ascertain the dose of BL-8040 will enroll a total of up to 30 subjects to an open labeled treatment to assess the efficacy, safety, PK and PD parameters of treatment with G-CSF 10 µg/kg/day and BL-8040 1.25mg/kg, per study protocol to goal collection of ≥ 6x106 CD34+ cells/kg. - Part 2: Following the successful completion of Part 1, a total of 177 subjects will be randomized into Part 2 of the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
BioLineRx Limited

  • Primary ID BL-8040.SCM.301
  • Secondary IDs NCI-2017-02287
  • ID NCT03246529